Statistics for Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration
Total visits
| views | |
|---|---|
| Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration | 163 |
Total visits per month
| views | |
|---|---|
| January 2024 | 0 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 0 |
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
File Visits
| views | |
|---|---|
| jop.2018.0062.pdf | 174 |
Top country views
| views | |
|---|---|
| United States | 125 |
| Germany | 9 |
| Ukraine | 5 |
| China | 3 |
| United Kingdom | 3 |
| Canada | 2 |
| Russia | 2 |
| Malaysia | 1 |
| Sweden | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 46 |
| Fairfield | 19 |
| Ann Arbor | 8 |
| Houston | 8 |
| Jacksonville | 6 |
| Kiez | 6 |
| Kiev | 5 |
| Cambridge | 4 |
| San Francisco | 4 |
| Beijing | 2 |
| Brooklyn | 2 |
| Gunzenhausen | 2 |
| Toronto | 2 |
| Baltimore | 1 |
| Chicago | 1 |
| Indianapolis | 1 |
| Moscow | 1 |
| Munich | 1 |
| Norwalk | 1 |
| Scottsdale | 1 |
| Seattle | 1 |
| Seremban | 1 |
| Shenzhen | 1 |
| Stockholm | 1 |
| Zheleznogorsk | 1 |